BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Aug 16, 2010
 |  BC Week In Review  |  Clinical News  |  Regulatory

Valcyte valganciclovir regulatory update

FDA approved an increased duration of therapy of Valcyte in adult kidney transplant patients at high risk for cytomegalovirus (CMV). The new label will include...

Read the full 101 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >